Skip to main content
Top
Published in: Substance Abuse Treatment, Prevention, and Policy 1/2020

Open Access 01-12-2020 | Buprenorphine | Research

Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway

Authors: Christer Frode Aas, Jørn Henrik Vold, Svetlana Skurtveit, Aaron G. Lim, Sabine Ruths, Kamrul Islam, Jan Erik Askildsen, Else-Marie Løberg, Lars Thore Fadnes, Kjell Arne Johansson, for the INTRO-HCV Study Group

Published in: Substance Abuse Treatment, Prevention, and Policy | Issue 1/2020

Login to get access

Abstract

Background

Opioid dependence carries the highest disease burden of all illicit drugs. Opioid agonist therapy (OAT) is an evidence-based medical intervention that reduces morbidity and mortality. There is limited knowledge on the health-related quality of life (HRQoL) of long-term patients in OAT. This study measures HRQoL and self-perceived health of long-term patients on OAT, compares the scores to a Norwegian reference population, and assesses changes in these scores at 1-year follow up.

Methods

We conducted a nested prospective cohort study among nine OAT outpatient clinics in Norway. 609 OAT patients were included, 245 (40%) followed-up one year later. Data on patient characteristics, HRQoL, and self-perceived health was collected. HRQoL was assessed with the EQ-5D-5L, which measures five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) on a five-point Likert scale (from “no problems” to “extreme problems”). An UK value set was applied to calculate index values (from 0 to 1) for the EQ-5D-5L and compare them to a Norwegian reference population. Self-perceived health was measured with EQ-VAS (from 0 to 100).

Results

Mean (standard deviation (SD)) EQ-5D-5L index value at baseline was 0.699 (0.250) and EQ-VAS 57 (22) compared to 0.848 (0.200) and 80(19) for the Norwegian reference population. There were large variations in EQ-5D-5L index values, where 43% had > 0.8 and 5% had < 0.2 at baseline. The lowest EQ-5D-5L index values were observed for female patients, age groups older than 40 years and for methadone users. At follow-up, improvements in HRQoL were observed across almost all dimensions and found significant for mobility and pain/discomfort. Mean (SD) overall index value and EQ-VAS at follow up were 0.729 (0.237) and 59 (22) respectively.

Conclusion

The average HRQoL and self-perceived health of OAT patients is significantly lower than that of the general population, and lower than what has been found among other severe somatic and psychiatric conditions. Around 34% had very good HRQoL, higher than average Norwegian values, and around 5% had extremely poor HRQoL.
Appendix
Available only for authorised users
Literature
2.
go back to reference Chang HY, Kharrazi H, Bodycombe D, Weiner JP, Alexander GC. Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study. BMC Med. 2018;16(1):69.PubMedPubMedCentral Chang HY, Kharrazi H, Bodycombe D, Weiner JP, Alexander GC. Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study. BMC Med. 2018;16(1):69.PubMedPubMedCentral
3.
go back to reference Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet (London, England). 2019;394(10208):1560–79. Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet (London, England). 2019;394(10208):1560–79.
4.
go back to reference Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Netw Open. 2018;1(2):e180217.PubMedPubMedCentral Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Netw Open. 2018;1(2):e180217.PubMedPubMedCentral
5.
go back to reference European Monitoring Centre for Drugs and Drug Addiction: European Drug Report. Trends and Developments. In.; 2019. European Monitoring Centre for Drugs and Drug Addiction: European Drug Report. Trends and Developments. In.; 2019.
6.
go back to reference Strada L, Vanderplasschen W, Buchholz A, Schulte B, Muller AE, Verthein U, Reimer J. Measuring quality of life in opioid-dependent people: a systematic review of assessment instruments. Qual Life Res. 2017;26(12):3187–200.PubMedPubMedCentral Strada L, Vanderplasschen W, Buchholz A, Schulte B, Muller AE, Verthein U, Reimer J. Measuring quality of life in opioid-dependent people: a systematic review of assessment instruments. Qual Life Res. 2017;26(12):3187–200.PubMedPubMedCentral
7.
go back to reference Millson P, Challacombe L, Villeneuve PJ, Strike CJ, Fischer B, Myers T, Shore R, Hopkins S. Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs. Eur Addict Res. 2006;12(2):74–82.PubMed Millson P, Challacombe L, Villeneuve PJ, Strike CJ, Fischer B, Myers T, Shore R, Hopkins S. Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs. Eur Addict Res. 2006;12(2):74–82.PubMed
8.
go back to reference Griffin ML, Bennett HE, Fitzmaurice GM, Hill KP, Provost SE, Weiss RD. Health-related quality of life among prescription opioid-dependent patients: results from a multi-site study. Am J Addict. 2015;24(4):308–14.PubMedPubMedCentral Griffin ML, Bennett HE, Fitzmaurice GM, Hill KP, Provost SE, Weiss RD. Health-related quality of life among prescription opioid-dependent patients: results from a multi-site study. Am J Addict. 2015;24(4):308–14.PubMedPubMedCentral
9.
go back to reference European Monitoring Centre for Drugs and Drug Addiction: Komorbiditet — samförekomst av narkotikamissbruk och psykisk störning. Ett underskattat tillstånd. In.; 2004. European Monitoring Centre for Drugs and Drug Addiction: Komorbiditet — samförekomst av narkotikamissbruk och psykisk störning. Ett underskattat tillstånd. In.; 2004.
10.
go back to reference Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, Johansson KA, Fadnes LT. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev Policy. 2020;15(1):44.PubMedPubMedCentral Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, Johansson KA, Fadnes LT. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev Policy. 2020;15(1):44.PubMedPubMedCentral
11.
go back to reference Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61(8):807–16.PubMed Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61(8):807–16.PubMed
12.
go back to reference Hall W. What have population surveys revealed about substance use disorders and their co-morbidity with other mental disorders? Drug Alcohol Rev. 1996;15(2):157–70.PubMed Hall W. What have population surveys revealed about substance use disorders and their co-morbidity with other mental disorders? Drug Alcohol Rev. 1996;15(2):157–70.PubMed
13.
go back to reference van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F, Crunelle CL, Swets M, Schoevers RA. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012;122(1–2):11–9. van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F, Crunelle CL, Swets M, Schoevers RA. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012;122(1–2):11–9.
14.
go back to reference Burdzovic Andreas J, Lauritzen G, Nordfjaern T. Co-occurrence between mental distress and poly-drug use: a ten year prospective study of patients from substance abuse treatment. Addict Behav. 2015;48:71–8.PubMed Burdzovic Andreas J, Lauritzen G, Nordfjaern T. Co-occurrence between mental distress and poly-drug use: a ten year prospective study of patients from substance abuse treatment. Addict Behav. 2015;48:71–8.PubMed
15.
go back to reference Mørkved N, Winje D, Dovran A, Arefjord K, Johnsen E, Kroken RA, Anda-Ågotnes LG, Thimm JC, Sinkeviciute I, Rettenbacher M, et al. Childhood trauma in schizophrenia spectrum disorders as compared to substance abuse disorders. Psychiatry Res. 2018;261:481–7.PubMed Mørkved N, Winje D, Dovran A, Arefjord K, Johnsen E, Kroken RA, Anda-Ågotnes LG, Thimm JC, Sinkeviciute I, Rettenbacher M, et al. Childhood trauma in schizophrenia spectrum disorders as compared to substance abuse disorders. Psychiatry Res. 2018;261:481–7.PubMed
16.
go back to reference Rosic T, Naji L, Bawor M, Dennis BB, Plater C, Marsh DC, Thabane L, Samaan Z. The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study. Neuropsychiatr Dis Treat. 2017;13:1399–408.PubMedPubMedCentral Rosic T, Naji L, Bawor M, Dennis BB, Plater C, Marsh DC, Thabane L, Samaan Z. The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study. Neuropsychiatr Dis Treat. 2017;13:1399–408.PubMedPubMedCentral
17.
go back to reference Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard Rev Psychiatry. 2015;23(2):63–75. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard Rev Psychiatry. 2015;23(2):63–75.
18.
go back to reference Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32–51.PubMed Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32–51.PubMed
19.
go back to reference Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B. Opioid-related treatment, interventions, and outcomes among incarcerated persons: a systematic review. PLoS Med. 2019;16(12):e1003002.PubMedPubMedCentral Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B. Opioid-related treatment, interventions, and outcomes among incarcerated persons: a systematic review. PLoS Med. 2019;16(12):e1003002.PubMedPubMedCentral
20.
go back to reference Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91(2):102–23.PubMedPubMedCentral Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91(2):102–23.PubMedPubMedCentral
21.
go back to reference Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, Degenhardt L, Farrell M, Blow FC, Ilgen M, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1868–83.PubMed Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, Degenhardt L, Farrell M, Blow FC, Ilgen M, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1868–83.PubMed
22.
go back to reference Bray JW, Aden B, Eggman AA, Hellerstein L, Wittenberg E, Nosyk B, Stribling JC, Schackman BR. Quality of life as an outcome of opioid use disorder treatment: a systematic review. J Subst Abus Treat. 2017;76:88–93. Bray JW, Aden B, Eggman AA, Hellerstein L, Wittenberg E, Nosyk B, Stribling JC, Schackman BR. Quality of life as an outcome of opioid use disorder treatment: a systematic review. J Subst Abus Treat. 2017;76:88–93.
23.
go back to reference Bullinger M. Assessing health related quality of life in medicine. An overview over concepts, methods and applications in international research. Restor Neurol Neurosci. 2002;20(3–4):93–101.PubMed Bullinger M. Assessing health related quality of life in medicine. An overview over concepts, methods and applications in international research. Restor Neurol Neurosci. 2002;20(3–4):93–101.PubMed
24.
go back to reference Muller AE, Skurtveit S, Clausen T. Confirming the factor structure of a generic quality of life instrument among pre-treatment substance use disorder patients. Health Qual Life Outcomes. 2019;17(1):84.PubMedPubMedCentral Muller AE, Skurtveit S, Clausen T. Confirming the factor structure of a generic quality of life instrument among pre-treatment substance use disorder patients. Health Qual Life Outcomes. 2019;17(1):84.PubMedPubMedCentral
25.
go back to reference Nosyk B, Bray JW, Wittenberg E, Aden B, Eggman AA, Weiss RD, Potter J, Ang A, Hser YI, Ling W, et al. Short term health-related quality of life improvement during opioid agonist treatment. Drug Alcohol Depend. 2015;157:121–8.PubMedPubMedCentral Nosyk B, Bray JW, Wittenberg E, Aden B, Eggman AA, Weiss RD, Potter J, Ang A, Hser YI, Ling W, et al. Short term health-related quality of life improvement during opioid agonist treatment. Drug Alcohol Depend. 2015;157:121–8.PubMedPubMedCentral
26.
go back to reference Lofwall MR, Brooner RK, Bigelow GE, Kindbom K, Strain EC. Characteristics of older opioid maintenance patients. J Subst Abus Treat. 2005;28(3):265–72. Lofwall MR, Brooner RK, Bigelow GE, Kindbom K, Strain EC. Characteristics of older opioid maintenance patients. J Subst Abus Treat. 2005;28(3):265–72.
27.
go back to reference Karow A, Verthein U, Pukrop R, Reimer J, Haasen C, Krausz M, Schafer I. Quality of life profiles and changes in the course of maintenance treatment among 1,015 patients with severe opioid dependence. Subst Use Misuse. 2011;46(6):705–15.PubMed Karow A, Verthein U, Pukrop R, Reimer J, Haasen C, Krausz M, Schafer I. Quality of life profiles and changes in the course of maintenance treatment among 1,015 patients with severe opioid dependence. Subst Use Misuse. 2011;46(6):705–15.PubMed
28.
go back to reference Millson PE, Challacombe L, Villeneuve PJ, Fischer B, Strike CJ, Myers T, Shore R, Hopkins S, Raftis S, Pearson M. Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations. Can J Public Health. 2004;95(2):99–103.PubMedPubMedCentral Millson PE, Challacombe L, Villeneuve PJ, Fischer B, Strike CJ, Myers T, Shore R, Hopkins S, Raftis S, Pearson M. Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations. Can J Public Health. 2004;95(2):99–103.PubMedPubMedCentral
29.
go back to reference Karow A, Reimer J, Schafer I, Krausz M, Haasen C, Verthein U. Quality of life under maintenance treatment with heroin versus methadone in patients with opioid dependence. Drug Alcohol Depend. 2010;112(3):209–15.PubMed Karow A, Reimer J, Schafer I, Krausz M, Haasen C, Verthein U. Quality of life under maintenance treatment with heroin versus methadone in patients with opioid dependence. Drug Alcohol Depend. 2010;112(3):209–15.PubMed
30.
go back to reference Hayes CJ, Li X, Li C, Shah A, Kathe N, Bhandari NR, Payakachat N. Health-related quality of life among chronic opioid users, nonchronic opioid users, and nonopioid users with chronic noncancer pain. Health Serv Res. 2018;53(5):3329–49.PubMedPubMedCentral Hayes CJ, Li X, Li C, Shah A, Kathe N, Bhandari NR, Payakachat N. Health-related quality of life among chronic opioid users, nonchronic opioid users, and nonopioid users with chronic noncancer pain. Health Serv Res. 2018;53(5):3329–49.PubMedPubMedCentral
31.
go back to reference Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgard O, Vickerman P, et al. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC Infect Dis. 2019;19(1):943.PubMedPubMedCentral Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgard O, Vickerman P, et al. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC Infect Dis. 2019;19(1):943.PubMedPubMedCentral
32.
go back to reference Waal H BK, Clausen T, Lillevold PH, and Skeie I.: SERAF Report: Status 2017. MAR 20 years. Status, evaluations and perspectives. In.: The Norwegian Centre for Addiction Research (SERAF); 2018. Waal H BK, Clausen T, Lillevold PH, and Skeie I.: SERAF Report: Status 2017. MAR 20 years. Status, evaluations and perspectives. In.: The Norwegian Centre for Addiction Research (SERAF); 2018.
34.
go back to reference Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann Med. 2001;33(5):337–43.PubMed Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann Med. 2001;33(5):337–43.PubMed
35.
go back to reference Peak J, Goranitis I, Day E, Copello A, Freemantle N, Frew E. Predicting health-related quality of life (EQ-5D-5 L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP. Health Qual Life Outcomes. 2018;16(1):106.PubMedPubMedCentral Peak J, Goranitis I, Day E, Copello A, Freemantle N, Frew E. Predicting health-related quality of life (EQ-5D-5 L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP. Health Qual Life Outcomes. 2018;16(1):106.PubMedPubMedCentral
36.
go back to reference van der Zanden BP, Dijkgraaf MG, Blanken P, de Borgie CA, van Ree JM, van den Brink W. Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population. Drug Alcohol Depend. 2006;82(2):111–8.PubMed van der Zanden BP, Dijkgraaf MG, Blanken P, de Borgie CA, van Ree JM, van den Brink W. Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population. Drug Alcohol Depend. 2006;82(2):111–8.PubMed
38.
go back to reference Buchholz I, Janssen MF, Kohlmann T, Feng YS. A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D. PharmacoEconomics. 2018;36(6):645–61.PubMedPubMedCentral Buchholz I, Janssen MF, Kohlmann T, Feng YS. A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D. PharmacoEconomics. 2018;36(6):645–61.PubMedPubMedCentral
39.
go back to reference Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22.PubMed Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22.PubMed
40.
go back to reference Stavem K, Augestad LA, Kristiansen IS, Rand K. General population norms for the EQ-5D-3 L in Norway: comparison of postal and web surveys. Health Qual Life Outcomes. 2018;16(1):204.PubMedPubMedCentral Stavem K, Augestad LA, Kristiansen IS, Rand K. General population norms for the EQ-5D-3 L in Norway: comparison of postal and web surveys. Health Qual Life Outcomes. 2018;16(1):204.PubMedPubMedCentral
41.
go back to reference Strada L, Schmidt CS, Rosenkranz M, Verthein U, Scherbaum N, Reimer J, Schulte B. Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: A cross-sectional study. Subst Abuse Treat Prev Policy. 2019;14(1):2.PubMedPubMedCentral Strada L, Schmidt CS, Rosenkranz M, Verthein U, Scherbaum N, Reimer J, Schulte B. Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: A cross-sectional study. Subst Abuse Treat Prev Policy. 2019;14(1):2.PubMedPubMedCentral
42.
go back to reference Waal HBK, Clausen T, Håseth A, Lillevold PH, Skeie I. SERAF Report: Status 2014, an aging MAR-population? Oslo: The Norwegian Centre for Addiction Research (SERAF); 2015. Waal HBK, Clausen T, Håseth A, Lillevold PH, Skeie I. SERAF Report: Status 2014, an aging MAR-population? Oslo: The Norwegian Centre for Addiction Research (SERAF); 2015.
43.
go back to reference Ministry of Health and Care Services. National guidline for medicaly assisted rehabilitation (MAR) for opioid dependence. Oslo: The Norwegian Ministry of Health and Care Services; 2010. Ministry of Health and Care Services. National guidline for medicaly assisted rehabilitation (MAR) for opioid dependence. Oslo: The Norwegian Ministry of Health and Care Services; 2010.
44.
go back to reference Braback M, Bradvik L, Troberg K, Isendahl P, Nilsson S, Hakansson A. Health related quality of life in individuals transferred from a needle exchange program and starting opioid agonist treatment. J Addict. 2018;2018:3025683.PubMedPubMedCentral Braback M, Bradvik L, Troberg K, Isendahl P, Nilsson S, Hakansson A. Health related quality of life in individuals transferred from a needle exchange program and starting opioid agonist treatment. J Addict. 2018;2018:3025683.PubMedPubMedCentral
45.
go back to reference Habrat B, Chmielewska K, Baran-Furga H, Keszycka B, Taracha E. Subjective quality of life in opiate-dependent patients before admission after six months and one-year participation in methadone program. Przeglad lekarski. 2002;59(4–5):351–4.PubMed Habrat B, Chmielewska K, Baran-Furga H, Keszycka B, Taracha E. Subjective quality of life in opiate-dependent patients before admission after six months and one-year participation in methadone program. Przeglad lekarski. 2002;59(4–5):351–4.PubMed
46.
go back to reference Ponizovsky AM, Grinshpoon A. Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse. 2007;33(5):631–42.PubMed Ponizovsky AM, Grinshpoon A. Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse. 2007;33(5):631–42.PubMed
47.
go back to reference Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010;8:18.PubMedPubMedCentral Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010;8:18.PubMedPubMedCentral
48.
go back to reference Stavem K, Froland SS, Hellum KB. Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Qual Life Res. 2005;14(4):971–80.PubMed Stavem K, Froland SS, Hellum KB. Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Qual Life Res. 2005;14(4):971–80.PubMed
49.
go back to reference Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Disability Weights. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2018; 2018. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Disability Weights. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2018; 2018.
51.
go back to reference Soyka M, Strehle J, Rehm J, Buhringer G, Wittchen HU. Six-year outcome of opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative sample. Eur Addict Res. 2017;23(2):97–105.PubMed Soyka M, Strehle J, Rehm J, Buhringer G, Wittchen HU. Six-year outcome of opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative sample. Eur Addict Res. 2017;23(2):97–105.PubMed
52.
go back to reference Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health. 2013;28(3–4):388–406.PubMedPubMedCentral Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health. 2013;28(3–4):388–406.PubMedPubMedCentral
53.
go back to reference Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. PharmacoEconomics. 2018;36(6):675–97.PubMedPubMedCentral Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. PharmacoEconomics. 2018;36(6):675–97.PubMedPubMedCentral
54.
go back to reference Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-5D three-level system with a five-level version. Value Health. 2008;11(2):275–84.PubMed Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-5D three-level system with a five-level version. Value Health. 2008;11(2):275–84.PubMed
Metadata
Title
Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway
Authors
Christer Frode Aas
Jørn Henrik Vold
Svetlana Skurtveit
Aaron G. Lim
Sabine Ruths
Kamrul Islam
Jan Erik Askildsen
Else-Marie Løberg
Lars Thore Fadnes
Kjell Arne Johansson
for the INTRO-HCV Study Group
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Substance Abuse Treatment, Prevention, and Policy / Issue 1/2020
Electronic ISSN: 1747-597X
DOI
https://doi.org/10.1186/s13011-020-00309-y

Other articles of this Issue 1/2020

Substance Abuse Treatment, Prevention, and Policy 1/2020 Go to the issue